- Home
- SRG vs PRQR Comparison
SRG vs PRQR Comparison
Compare SRG & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- PRQR
- Stock Information
- Founded
- SRG 2014
- PRQR 2012
- Country
- SRG United States
- PRQR Netherlands
- Employees
- SRG N/A
- PRQR N/A
- Industry
- SRG Real Estate Investment Trusts
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- SRG Real Estate
- PRQR Health Care
- Exchange
- SRG Nasdaq
- PRQR Nasdaq
- Market Cap
- SRG 163.3M
- PRQR 179.1M
- IPO Year
- SRG 2015
- PRQR 2014
- Fundamental
- Price
- SRG $3.16
- PRQR $2.18
- Analyst Decision
- SRG
- PRQR Strong Buy
- Analyst Count
- SRG 0
- PRQR 8
- Target Price
- SRG N/A
- PRQR $8.88
- AVG Volume (30 Days)
- SRG 93.5K
- PRQR 371.0K
- Earning Date
- SRG 08-13-2025
- PRQR 08-07-2025
- Dividend Yield
- SRG N/A
- PRQR N/A
- EPS Growth
- SRG N/A
- PRQR N/A
- EPS
- SRG N/A
- PRQR N/A
- Revenue
- SRG N/A
- PRQR $21,212,711.00
- Revenue This Year
- SRG N/A
- PRQR N/A
- Revenue Next Year
- SRG N/A
- PRQR N/A
- P/E Ratio
- SRG N/A
- PRQR N/A
- Revenue Growth
- SRG N/A
- PRQR 85.91
- 52 Week Low
- SRG $2.43
- PRQR $1.07
- 52 Week High
- SRG $5.52
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- SRG 52.19
- PRQR 65.20
- Support Level
- SRG $2.94
- PRQR $1.89
- Resistance Level
- SRG $3.18
- PRQR $2.54
- Average True Range (ATR)
- SRG 0.11
- PRQR 0.13
- MACD
- SRG 0.01
- PRQR 0.01
- Stochastic Oscillator
- SRG 46.06
- PRQR 39.85
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.